Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (161-170 of 484) with videos related to

Pageof 49
Sort By:
Molecular & Cellular Proteomics : MCP|November 15, 2008
Urine metabolomics analysis for kidney cancer detection and biomarker discoveryKyoungmi Kim, Pavel Aronov, Stanislav O Zakharkin, et al.
The Journal of Urology|June 14, 2008
Total prostate specific antigen stability confirmed after long-term storage of serum at -80CAmanda Beth Reed, Donna Pauler Ankerst, Robin J Leach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical TrialsCatherine M Tangen, Phyllis J Goodman, Cathee Till, et al.
Annals of Translational Medicine & Epidemiology|January 27, 2015
Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 DiabetesWang Chen-Pin, Hernandez Javier, Carlos Lorenzo, et al.
The Prostate|January 1, 2008
Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatmentYoonJu Song, Catherine Tangen, Phyllis Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
Hematology/Oncology Clinics of North America|July 25, 2006
Chemoprevention of prostate cancerTimothy C Brand, Edith D Canby-Hagino, A Pratap Kumar, et al.
The Journal of Urology|May 16, 2006
The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman, Ian M Thompson, Catherine M Tangen, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Urologia Internationalis|May 26, 2012
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation studyYuanyuan Liang, Norma S Ketchum, Christopher Louden, et al.
Pageof 49

Showing results (161-170 of 484) with videos related to

Sort By:
Pageof 49
Molecular & Cellular Proteomics : MCP|November 15, 2008
Urine metabolomics analysis for kidney cancer detection and biomarker discoveryKyoungmi Kim, Pavel Aronov, Stanislav O Zakharkin, et al.
The Journal of Urology|June 14, 2008
Total prostate specific antigen stability confirmed after long-term storage of serum at -80CAmanda Beth Reed, Donna Pauler Ankerst, Robin J Leach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical TrialsCatherine M Tangen, Phyllis J Goodman, Cathee Till, et al.
Annals of Translational Medicine & Epidemiology|January 27, 2015
Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 DiabetesWang Chen-Pin, Hernandez Javier, Carlos Lorenzo, et al.
The Prostate|January 1, 2008
Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatmentYoonJu Song, Catherine Tangen, Phyllis Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
Hematology/Oncology Clinics of North America|July 25, 2006
Chemoprevention of prostate cancerTimothy C Brand, Edith D Canby-Hagino, A Pratap Kumar, et al.
The Journal of Urology|May 16, 2006
The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman, Ian M Thompson, Catherine M Tangen, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Urologia Internationalis|May 26, 2012
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation studyYuanyuan Liang, Norma S Ketchum, Christopher Louden, et al.
Pageof 49